Benitec Biopharma (BNTC) to Release Earnings on Friday

Benitec Biopharma (NASDAQ:BNTC) is anticipated to post its Q2 2026 results before the market opens on Friday, February 13th. Analysts expect Benitec Biopharma to post earnings of ($0.23) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, February 13, 2026 at 4:00 PM ET.

Benitec Biopharma (NASDAQ:BNTC) last released its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.13. On average, analysts expect Benitec Biopharma to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Benitec Biopharma Price Performance

Shares of Benitec Biopharma stock opened at $11.65 on Friday. Benitec Biopharma has a 12 month low of $9.70 and a 12 month high of $17.15. The stock has a market capitalization of $399.13 million, a price-to-earnings ratio of -9.63 and a beta of 0.26. The business has a 50-day moving average of $12.43 and a 200 day moving average of $13.15.

Insider Buying and Selling

In related news, Director Suvretta Capital Management, L purchased 77,387 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The stock was acquired at an average cost of $13.44 per share, for a total transaction of $1,040,081.28. Following the completion of the acquisition, the director owned 9,700,195 shares in the company, valued at $130,370,620.80. This trade represents a 0.80% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last three months, insiders bought 190,364 shares of company stock worth $2,442,105. Company insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On Benitec Biopharma

Institutional investors have recently bought and sold shares of the stock. UBS Group AG boosted its holdings in shares of Benitec Biopharma by 458.8% during the 3rd quarter. UBS Group AG now owns 99,941 shares of the biotechnology company’s stock worth $1,402,000 after buying an additional 82,057 shares during the period. Ameriprise Financial Inc. raised its stake in Benitec Biopharma by 219.4% during the second quarter. Ameriprise Financial Inc. now owns 109,925 shares of the biotechnology company’s stock worth $1,286,000 after acquiring an additional 75,507 shares in the last quarter. Marshall Wace LLP acquired a new stake in Benitec Biopharma during the 2nd quarter valued at $503,000. XTX Topco Ltd acquired a new stake in shares of Benitec Biopharma in the second quarter valued at approximately $127,000. Finally, Rhumbline Advisers raised its holdings in Benitec Biopharma by 11,114.0% during the 2nd quarter. Rhumbline Advisers now owns 20,858 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 20,672 shares during the last quarter. 52.19% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Citigroup restated an “outperform” rating on shares of Benitec Biopharma in a research note on Tuesday, November 4th. Zacks Research raised Benitec Biopharma from a “strong sell” rating to a “hold” rating in a report on Friday, November 14th. HC Wainwright set a $32.00 price objective on Benitec Biopharma and gave the stock a “buy” rating in a report on Monday, November 24th. Wall Street Zen upgraded Benitec Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Finally, JMP Securities set a $22.00 target price on shares of Benitec Biopharma in a research note on Tuesday, November 4th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $26.25.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.